Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157928 | 0.79 | CYP3A4 (0.71) | CYP3A4ADORA2BADORA3GAAALDH1A1 | |
| SCHEMBL5443892 | 0.79 | GAA (0.43) | CYP3A4MAPTADORA2BPOLBADORA3 | |
| SCHEMBL11077876 | 0.77 | CYP3A4 (0.68) | CYP3A4ADORA2BADORA3GAAALDH1A1 | |
| SCHEMBL1546553 | 0.76 | MAPT (0.67) | CYP3A4MAPTADORA2BPOLBADORA3 | |
| SCHEMBL5441771 | 0.76 | ADORA2B (0.46) | CYP3A4ADORA2BADORA3GAAALDH1A1 | |
| SCHEMBL4759502 | 0.74 | CYP3A4 (0.58) | CYP3A4MAPTADORA2BADORA3GAA | |
| SCHEMBL1945331 | 0.73 | KDM4E (0.64) | MAPTPOLBGAAALDH1A1KDM4E | |
| SCHEMBL1565331 | 0.73 | MAPT (0.69) | MAPTADORA2BPOLBADORA3GAA | |
| SCHEMBL181982 | 0.73 | CYP3A4 (0.54) | CYP3A4MAPTADORA2BADORA3GAA | |
| SCHEMBL1945300 | 0.72 | MAPT (0.32) | MAPTPOLBSMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2021-06-08 | — | — | US | disclosed |
| EP-3490996-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2020-08-26 | — | — | EP | disclosed |
| US-20200262847-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-08-20 | — | — | US | disclosed |
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-06-16 | — | — | US | disclosed |
| EP-3490996-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2019-06-05 | — | — | EP | disclosed |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2019-05-30 | — | — | US | disclosed |
| EP-3262044-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-22 | — | — | US | disclosed |
| WO-2018019917-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-01 | — | — | WO | disclosed |
| EP-3275885-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016135199-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-09-01 | — | — | WO | disclosed |
| EP-3061761-A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-7253176-B1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-0956855-B1 | Immunosuppressive effects of 8 substituted xanthine derivatives | LEUVEN K U RES & DEV (BE) | 2003-03-12 | — | — | EP | disclosed |
| EP-0956855-A1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. Leuven Research & Development (BE) | 1999-11-17 | — | — | EP | disclosed |
| EP-0619316-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-08-12 | — | — | EP | disclosed |
| US-5395836-A | Adenosine A1 receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5290782-A | Bronchodilator agents, diuretics for renal protective agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0501379-A2 | Xanthine compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | TPH1, XDH, TPH2 | CYP3A4 107/4885MAPT 1088/4885ADORA2B 441/4885 |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | CYP3A4 107/4885MAPT 1088/4885ADORA2B 441/4885 |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | CYP3A4 107/4885MAPT 1088/4885ADORA2B 441/4885 |
| US-20200262847-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | CYP3A4 107/4885MAPT 1088/4885ADORA2B 441/4885 |
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | TPH1, XDH, TPH2 | CYP3A4 107/4885MAPT 1088/4885ADORA2B 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.